Neurocrine Biosciences, Inc. NBIX
Set alert
At close · Oct 30
After hours · Oct 30, 5:09 PM ET
- YTD
- +3.01%
- 1 year
- +5.84%
- Open
- 147.13
- Prev close
- 146.38
- Mkt cap
- 14.85B
- Vol
- 1.32M
- Avg vol
- 1.29M
- EPS
- 6.82
- P/E
- 21.42
- Div yield
- 0.00%
More statistics
- Low
- 145.22
- High
- 149.25
- Forward P/E
- 12.20
- Beta
- 0.40
- Short ratio
- 4.41
- Inst. own
- 104.21%
- Dividend
- 0.00
- Ex-div date
- Dec 28, 1995
- Earnings
- Nov 2, 2026
- 50-d avg
- 146.77
- 200-d avg
- 147.33
- 1y target
- 206.22
5D chart
Signals (144)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:10 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:30 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
7 hours ago benzinga.com
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
2 days ago zacks.com
Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 days ago prnewswire.com
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides…
6 days ago zacks.com
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
6 days ago benzinga.com
Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
6 days ago prnewswire.com
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with…
1 week ago fool.com
Where Will Neurocrine Biosciences Be in 5 Years?
Ingrezza remains Neurocrine's biggest revenue driver, with sales growing 15%. Two late-stage drug candidates face important clinical milestones in 2027.
-
1 week ago benzinga.com
Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition
Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
1 week ago prnewswire.com
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
-
1 week ago benzinga.com
Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's…
1 week ago prnewswire.com
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in…
-
2 weeks ago benzinga.com
Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among…
2 weeks ago prnewswire.com
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records…
-
2 weeks ago benzinga.com
Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.
2 weeks ago zacks.com
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 weeks ago zacks.com
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies…
2 weeks ago zacks.com
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 weeks ago defenseworld.net
Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)
Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
2 weeks ago prnewswire.com
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third…
-
2 weeks ago benzinga.com
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.
3 weeks ago zacks.com
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
-
3 weeks ago benzinga.com
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.
3 weeks ago 247wallst.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and More
Pre-Market Stock Futures: Futures are trading higher after we started off the first full trading week of the undefined quarter in solid style, as all major indices finished the day higher despite…
1 month ago prnewswire.com
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will…
-
1 month ago benzinga.com
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.
1 month ago prnewswire.com
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.
1 month ago marketbeat.com
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the…
1 month ago defenseworld.net
Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX
Integrated Wealth Concepts LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 41.5% during the second quarter, according to the company in its most recent filing with the…
1 month ago defenseworld.net
Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX
Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported…
4 months ago benzinga.com
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys
Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.
6 months ago benzinga.com
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
6 months ago benzinga.com
Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market
Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
8 months ago benzinga.com
McDonald's To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday
McDonald's To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday
-
8 months ago benzinga.com
Earnings Scheduled For February 11, 2026
Earnings Scheduled For February 11, 2026
11 months ago benzinga.com
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
11 months ago benzinga.com
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday
1 year ago benzinga.com
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday?
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100…
1 year ago benzinga.com
Earnings Scheduled For October 28, 2025
Earnings Scheduled For October 28, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
1 year ago benzinga.com
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For February 6, 2025
Earnings Scheduled For February 6, 2025